Absci (ABSI) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Absci Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Absci is: No Data: Cannot be evaluated.

Competitive Comparison of Absci's Risk Assessment

For the Biotechnology subindustry, Absci's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Absci's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Absci's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Absci's Risk Assessment falls into.

Absci (NAS:ABSI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Absci Risk Assessment Related Terms

Thank you for viewing the detailed overview of Absci's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Absci (ABSI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683

Website

https://www.absci.com

Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Executives

Frans Van Houten	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj	director	400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch	director	C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman	officer: General Counsel	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick	officer: VP, CCPAO	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh	director	C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain	director, 10 percent owner, officer: President and Chief Executive	18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson	director	18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin	director, 10 percent owner	1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p.	director, 10 percent owner	WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis	director	INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p.	director, 10 percent owner	LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc	10 percent owner	1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel	officer: Chief Business Officer	101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660